Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients

Nephrology

Volumn 14, Issue 6, 2009, Pages 560-564

  Tsouchnikas, Ioannis ^a   Dounousi, Evangelia ^a   Papakonstantinou, Stamatina ^a   Ioannou, Kyriakos ^a   Kelesidis, Apostolos ^a   Kotzadamis, Nikolaos ^a   Xanthopoulou, Kyriaki ^a   Tsakiris, Dimitrios ^a  

^a GENERAL HOSPITAL OF VERIA   (Greece)

Author keywords

Atorvastatin; C reactive protein; Dyslipidemia; Erythropoietin resistance; Haemodialysis

Indexed keywords

ALBUMIN; ATORVASTATIN; C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; TRIACYLGLYCEROL;

AGED; ANEMIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEPLETION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; ERYTHROPOIETIN; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS;

EID: 69449084923     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01084.x     Document Type: Article

References (41)

1. National Kidney Foundation. NKF K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am. J. Kidney Dis. 2001 37 (Suppl 1 S182 238.
2. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol. Dial. Transplant. 2001 16 (Suppl 7 25 8.
3. Gunell G, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. 1999 33 : 63 72.
4. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates the risk prediction based on the Framingham Score: Implications for future risk assessment: Results from a large cohort study in Southern Germany. Circulation 2004 109 : 1349 1353.
5. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004 109 : 1955 1959.
6. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 55 : 648 658.
7. Yeun JY, Levine RA, Mantalidok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2000 35 : 469 476.
8. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am. J. Kidney Dis. 1997 29 : 565 568.
9. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am. J. Kidney Dis. 2003 42 : 761 773.
10. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in hemodialysis patients. Nephrol. Dial. Transplant. 2006 21 : 991 998.
11. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis. 1998 32 : S142 56.
12. Scandinavian Simvastatin Survival Study Group. Randimised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 1389.
13. Seliger SL, Weiss NS, Gillen DL et al. HMG-COA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002 61 : 297 304.
14. Davignon J. Cardioprotective and other emerging effects of statins. Int. J. Clin. Pract. Suppl. 2004 143 : 49 57.
15. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001 286 : 64 70.
16. Vernaglione L, Cristofano C, Muscogiuri P, Chiementi S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am. J. Kindey Dis. 2004 43 : 471 478.
17. Tsirpanlis G, Boufidou F, Manganas S et al. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif. 2004 22 : 518 524.
18. Van den Akker JM, Brendle SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: Effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J. Nephrol. 2003 16 : 238 244.
19. Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005 25 : 335 344.
20. Sirken G, Kung SC, Raja R. Decrease erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J. 2003 49 : 422 425.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am. J. Kidney Dis. 2003 41 (Suppl 3 S39 58.
22. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 2497.
23. Nakamoto H, Kanno Y, Okada H, Suzuki H. Erythropoietin resistance in patients on continuous peritoneal dialysis. Adv. Perit. Dial. 2004 20 : 111 116.
24. Schwenk MH, Jumani AQ, Rosenberg CR et al. Potential angiotensin- converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis. Pharmacotherapy 1998 18 : 627 630.
25. Abu-Alfa AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am. J. Kidney Dis. 2000 35 : 1076 1082.
26. Chang JW, Yang SW, Min WK, Lee SK, Park JS, Kim SB. Effect of simvastatin of high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am. J. Kidney Dis. 2002 39 : 1213 1217.
27. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005 353 : 238 248. (Pubitemid 41058323)
28. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Reccurent Events (CARE) investigators. Circulation 1999 100 : 230 235.
29. Bays HE, Stein EA, Shan AK, Maccubin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am. J. Cardiol. 2002 90 : 942 946.
30. Ichikara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in hemodialysis patients with type 2 diabetes mellitus. Nephrol. Dial. Transplant. 2002 17 : 1513 1517.
31. Panichi V, Paoletti S, Mantuano E et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol. Dial. Transplant. 2006 21 : 337 344.
32. Ikejiri A, Hirano T, Murayama S et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004 53 : 1113 1117.
33. Drueke T, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006 355 : 2071 2084.
34. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa is chronic kidney disease. N. Engl. J. Med. 2006 355 : 2085 2098.
35. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002 106 : 1447 1452.
36. Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am. Heart J. 2003 145 : e8.
37. Navaro JF, Mora C, Muros M, Garcia-Idoate G. Effects of atorvastatin on lipid profile and non-traditional cardiovascular factors in diabetic patients on hemodialysis. Nephron. Clin. Pract. 2003 95 : e105 6.
38. Kalantar-Zadeh K, Kleiner M, Dunne E et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am. J. Kidney Dis. 1998 31 : 263 272.
39. Revised European Best Practice Guidelines for the management of Anemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004 19 (Suppl 2 39 41.
40. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J. Am. Soc. Nephrol. 1996 7 : 2654 2657. (Pubitemid 27469573)
41. National Kidney Foundation. NKF K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am. J. Kidney Dis. 2006 47 (Suppl 3 S58 70.